top of page
  • Writer's pictureMedMira

Progress Update on MedMira’s COVID-19 Product Family

Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection. Once extensively validated, MedMira’s neutralizing antibody test can effectively pinpoint the antibodies with the blocking capability, potentially, serving as a powerful tool for the qualitative assessment of the antibody status pre- and post-vaccination, as well as providing insights into one’s immunity to SARS-CoV-2. At this time, there is no guarantee that this product will meet all regulatory requirements and receive a subsequent regulatory approval.


“Over the past twenty years, our Research and Development group has played a crucial role in the development of the innovative diagnostic solutions, which allowed us to quickly adapt our RVF® platform and develop this neutralizing antibody test prototype that will greatly complement the current serology assays, including MedMira’s REVEALCOVID-19™ PLUS Total Antibody Test,” said Hermes Chan, CEO of MedMira. “For instance, a positive antibody result indicates that you have antibodies in general, while a positive neutralizing antibody test may tell you how effective these antibodies are. This is yet another milestone in the expansion of our COVID-19 product family, and we are excited about what is coming up next.”


MedMira is committed to offering an array of high-quality COVID-19 products to address various global market needs and reflect upon the scientific breakthroughs. Regulatory update as well as the latest product development strategy will be publicly announced soon.


Kommentare


bottom of page